Pharmacokinetic Drug–Drug Interaction of the Novel Anticancer Agent E7070 and Acenocoumarol

Author： van den Bongard H.J.G. Desirée   Sparidans Rolf W.   Critchley David J.P.   Beijnen Jos H.   Schellens Jan H.M.  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.22, Iss.2, 2004-04, pp. : 151-158

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

What is the true risk of a pharmacokinetic drug–drug interaction?

By Fuhr Uwe  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 10, 2007-10 ,pp. : 897-899

Springer Publishing Company

Access to resources Recommend Favorite

Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment

By Gschwind Liliane   Rollason Victoria   Boehlen Françoise   Rebsamen Michela   Combescure Christophe   Grünenwald Michèle   Matthey Alain   Bonnabry Pascal   Dayer Pierre   Desmeules Jules Alexandre  

Pharmacogenomics, Vol. 14, Iss. 7, 2013-05 ,pp. : 745-753

Future Medicine

Access to resources Recommend Favorite

Lack of Pharmacokinetic Drug-Drug Interaction between Orlistat and Cerivastatin

By Mück W.   Adelmann H-G.   Ruf T.   Unger S.   Voith B.  

Clinical Drug Investigation, Vol. 19, Iss. 1, 2000-01 ,pp. : 71-73

Adis International

Access to resources Recommend Favorite

Drug-Drug Interaction Prediction Assessment

By Zhou Jihao  

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 4, 2009-07 ,pp. : 641-657

Taylor & Francis Ltd

Access to resources Recommend Favorite

Drug-Drug Interaction Pattern Recognition

By Duan John Z.  

Drugs in R&D, Vol. 10, Iss. 1, 2010-05 ,pp. : 9-24

Adis International

Access to resources Recommend Favorite